Arspura Showcases a New Standard for Healthy Kitchen Living at CES 2026 
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27
SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical...
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27
SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical...
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27
SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical...
Stemtech Corporation – Stemtech Healthsciences India Pvt Ltd Announces Strategy for Market Entry
NAPLES, FL / ACCESS Newswire / October 27, 2025 / "STEMTECH CORPORATION", the global leader and pioneer in stem cell...
Stemtech Corporation – Stemtech Healthsciences India Pvt Ltd Announces Strategy for Market Entry
NAPLES, FL / ACCESS Newswire / October 27, 2025 / "STEMTECH CORPORATION", the global leader and pioneer in stem cell...
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27
SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical...
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences
Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of...
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences
Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of...
Stemtech Corporation – Stemtech Healthsciences India Pvt Ltd Announces Strategy for Market Entry
NAPLES, FL / ACCESS Newswire / October 27, 2025 / "STEMTECH CORPORATION", the global leader and pioneer in stem cell...
Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial
Orchestra BioMed’s Virtue® Sirolimus AngioInfusionTM Balloon (“Virtue SAB”) is the first non-coated drug-eluting balloon system designed to deliver a large...
Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial
Orchestra BioMed’s Virtue® Sirolimus AngioInfusionTM Balloon (“Virtue SAB”) is the first non-coated drug-eluting balloon system designed to deliver a large...
Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial
Orchestra BioMed’s Virtue® Sirolimus AngioInfusionTM Balloon (“Virtue SAB”) is the first non-coated drug-eluting balloon system designed to deliver a large...
Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial
Orchestra BioMed’s Virtue® Sirolimus AngioInfusionTM Balloon (“Virtue SAB”) is the first non-coated drug-eluting balloon system designed to deliver a large...
Curia Invests $4 Million to Enhance Sterile API Manufacturing
ALBANY, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), a leading global research, development and manufacturing organization,...
Curia Invests $4 Million to Enhance Sterile API Manufacturing
ALBANY, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), a leading global research, development and manufacturing organization,...
Curia Invests $4 Million to Enhance Sterile API Manufacturing
ALBANY, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), a leading global research, development and manufacturing organization,...
Curia Invests $4 Million to Enhance Sterile API Manufacturing
ALBANY, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), a leading global research, development and manufacturing organization,...
Trinity Biotech Welcomes Perceptive Advisor’s Indication of Potential Debt-to-Equity Conversion – Strengthening Balance Sheet and Supporting Growth
DUBLIN, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics...
Trinity Biotech Welcomes Perceptive Advisor’s Indication of Potential Debt-to-Equity Conversion – Strengthening Balance Sheet and Supporting Growth
DUBLIN, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics...
Trinity Biotech Welcomes Perceptive Advisor’s Indication of Potential Debt-to-Equity Conversion – Strengthening Balance Sheet and Supporting Growth
DUBLIN, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics...